RxDoctor Payments Data

David Reichel, MD

Internal Medicine · Sarasota, FLNPI 1508867458

Payments from drug & device makers

$921in general payments, 2019–2025

Across 44 payments — averaging $20.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$268
  • Novo Nordisk$156
  • Astellas Pharma US Inc$110
  • Novartis$86
  • Pfizer$75
  • Exact Sciences$70
  • plus $157 from 5 others

What the payments were for

  • Food & beverage$921100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$921 in reported general payments places this provider in the 65th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$573,338
Medicare patients
1,186
Services billed
12,783

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban166$185,942
MounjaroTirzepatide109$166,266
XareltoRivaroxaban65$82,725
JardianceEmpagliflozin51$80,399
OzempicSemaglutide62$78,906
FarxigaDapagliflozin Propanediol84$76,333
JanuviaSitagliptin Phosphate43$66,525
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$54,239
JanumetSitagliptin Phos/Metformin Hcl18$29,746
RybelsusSemaglutide13$27,531
MyrbetriqMirabegron25$23,308
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog30$18,862
Rosuvastatin Calcium877$11,543
PremarinEstrogens, Conjugated23$9,545
Breo ElliptaFluticasone/Vilanterol13$8,651

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$75$195,488189 claims
Lilly USA, LLCMounjaro$268$166,266109 claims
Novo NordiskOzempic, Rybelsus$156$106,43775 claims
MerckJanuvia, Janumet$16$96,27061 claims
Johnson & JohnsonXarelto$38$82,72565 claims
GSKTrelegy Ellipta, Breo Ellipta$32$62,89057 claims
Astellas Pharma US IncMyrbetriq$110$23,30825 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →